Skip to main content

Table 6 Comparison with recent US and German studies

From: A new paradigm evaluating cost per cure of HCV infection in the UK

Patients characteristics

Current study (n = 154)

Stahmeyer et al. (GER) [35] (n = 858)*

Bichoupan et al. (US) [17] (n = 147)

Age, years [Mean, (SD)]

49.6 (9.0)

49.2 (11.2)

56 (IQR = 51–61)

Gender, Male [%]

73.4

58

68

Ethnicity, %

   

 Caucasian [%]

94.20 %

97.30 %

Not reported

 Asian [%]

2.70 %

0.90 %

Not reported

 African [%]

1.30 %

0.80 %

19 %

 Hispanic [%]

Not reported

0.50 %

Not reported

 Other [%]

1.80 %

Not reported

Not reported

SVR rate by therapy

   

 BOC [%]

60.8

58.1

Not reported

 TVR [%]

63.1

68.4

44

Cirrhosis [%]

21.40 %

Not reported

36 %

Prior non-responders [%]

22.10 %

Not reported

46 %

Cost drivers

   

 Drug costs

94.60 %

94.6–97.7 %

89 %

 PIs

68.30 %

Not reported

Not reported

 TVR

Not reported

Not reported

61

 PegIFN

19.50 %

Not reported

24 %

 RBV

6.80 %

Not reported

4 %

Outpatient and inpatient care (incl AEs & follow-up)

5.40 %

5.4-3.3 %

8 %

Cost per SVR ($)

   

 Treatment naïve

56,576

73,473–82,756

Not reported

 Relapsers

58,353

78,529–93,758

Not reported

 Non-responders

125,125

127,1049–132,204

Not reported

 Overall

Not reported

Not reported

189,000

  1. *Costs from Stahmeyer et al. were converted from euros to US dollars (conversion rate: €1 = $1.0985 based on European Central Bank exchange rates, March 2015)